Stifel Maintains Buy on Privia Health Gr, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Craig Jones maintains a Buy rating on Privia Health Group (PRVA) but lowers the price target from $28 to $24.

May 01, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Stifel maintains a Buy rating on Privia Health Group but lowers the price target from $28 to $24.
While the reduction in price target could suggest a tempered outlook on PRVA's short-term price performance, the maintenance of a Buy rating indicates continued confidence in the company's fundamentals and long-term growth potential. This mixed signal could lead to neutral short-term price movement as investors weigh the lowered price target against the analyst's ongoing endorsement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100